Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)
- PMID: 37218537
- DOI: 10.1002/dmrr.3646
Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)
Abstract
The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. This is the first guideline on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes published by the IWGDF. We followed the GRADE Methodology to devise clinical questions in the PACO (Population, Assessment, Comparison, Outcome) and PICO (Population, Intervention, Comparison, Outcome) format, conducted a systematic review of the medical literature, and developed recommendations with the rationale. The recommendations are based on the evidence from our systematic review, expert opinion when evidence was not available, and also taking into account weighing of the benefits and harms, patient preferences, feasibility and applicability, and costs related to an intervention. We here present the 2023 Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus and also suggest key future topics of research.
Keywords: Charcot foot; Charcot neuro-osteoarthropathy; Charcot neuroarthropathy; Charcot osteoarthropathy; diabetic foot; guidelines.
© 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Similar articles
-
Diagnosis and treatment of active charcot neuro-osteoarthropathy in persons with diabetes mellitus: A systematic review.Diabetes Metab Res Rev. 2024 Mar;40(3):e3653. doi: 10.1002/dmrr.3653. Epub 2023 May 14. Diabetes Metab Res Rev. 2024. PMID: 37179484
-
Reviewing recommendations from the IWGDF 2023 guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy: highlighting the role of temperature monitoring with illustrative case reports.Wounds. 2024 Jun;36(6):206-211. doi: 10.25270/wnds/24029. Wounds. 2024. PMID: 39018364
-
Review and Evaluation of European National Clinical Practice Guidelines for the Treatment and Management of Active Charcot Neuro-Osteoarthropathy in Diabetes Using the AGREE-II Tool Identifies an Absence of Evidence-Based Recommendations.J Diabetes Res. 2024 Jun 10;2024:7533891. doi: 10.1155/2024/7533891. eCollection 2024. J Diabetes Res. 2024. PMID: 38899148 Free PMC article. Review.
-
Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update).Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3269. doi: 10.1002/dmrr.3269. Diabetes Metab Res Rev. 2020. PMID: 32176451
-
The Diabetic Charcot Foot from 1936 to 2016: Eighty Years Later and Still Growing.Clin Podiatr Med Surg. 2017 Jan;34(1):1-8. doi: 10.1016/j.cpm.2016.07.001. Epub 2016 Sep 3. Clin Podiatr Med Surg. 2017. PMID: 27865310 Review.
Cited by
-
Assessment of bone marrow edema on dual-energy CT scans in people with diabetes mellitus and suspected Charcot neuro-osteoarthropathy.Skeletal Radiol. 2025 Jan;54(1):105-112. doi: 10.1007/s00256-024-04714-3. Epub 2024 Jun 4. Skeletal Radiol. 2025. PMID: 38833168 Free PMC article.
-
Identification and interpretation of risk factors for Charcot foot.Diabetologia. 2025 May;68(5):1076-1077. doi: 10.1007/s00125-025-06386-7. Epub 2025 Feb 20. Diabetologia. 2025. PMID: 39976725 No abstract available.
-
Infrared Dermal Thermometry in Active Charcot Neuro-Osteoarthropathy of Foot.Indian J Endocrinol Metab. 2025 May-Jun;29(3):303-307. doi: 10.4103/ijem.ijem_447_24. Epub 2025 Jun 28. Indian J Endocrinol Metab. 2025. PMID: 40688622 Free PMC article.
-
Intra-Observer and Inter-Observer Reliability of Ankle Circumference Measurement in Patients with Diabetic Foot: A Prospective Observational Study.J Clin Med. 2023 Nov 18;12(22):7166. doi: 10.3390/jcm12227166. J Clin Med. 2023. PMID: 38002778 Free PMC article.
-
Factors associated with the development of recurrent and contralateral Charcot neuroarthropathy in individuals with diabetes mellitus: A scoping review.J Foot Ankle Res. 2024 Dec;17(4):e70016. doi: 10.1002/jfa2.70016. J Foot Ankle Res. 2024. PMID: 39550635 Free PMC article.
References
REFERENCES
-
- Metcalf L, Musgrove M, Bentley J, et al. Prevalence of active Charcot disease in the East Midlands of England. Diabet Med. 2018;35(10):1371-1374. https://doi.org/10.1111/dme.13679
-
- O'Loughlin A, Kellegher E, McCusker C, Canavan R. Diabetic charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre. Ir J Med Sci. 2017;186(1):151-156. https://doi.org/10.1007/s11845-016-1508-5
-
- Svendsen OL, Rabe OC, Winther-Jensen M, Allin KH. How common is the rare Charcot foot in patients with diabetes? Diabetes Care. 2021;44(4):e62-e3. https://doi.org/10.2337/dc20-2590
-
- International Diabetes Foundation. IDF Diabetes Atlas 10th Edition; 2021. Accessed 9 August 2022. https://www.diabetesatlas.org
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical